Navigation Links
Immunotech Laboratories Appoints New Chief Financial Advisor to Strengthen Company's Growth and International Expansion Plan
Date:2/7/2013

PASADENA, Calif., Feb. 7, 2013 /PRNewswire/ --

Immunotech Laboratories, Inc. (PINKSHEETS : IMMB ) Immunotech Laboratories, Inc., today announced the appointment of Mr. Valentin Dimitrov to the company Board of Directors as Chief Financial Advisor effective immediately.

Mr. Dimitrov (48) has an impressive professional history in the International Pharmaceutical World along with an impressive background in the formation and management of International Corporations, including the founding member and supervisory Board Chairman of the International Orthodox Bank – (present "Investbank" JSC).

Immunotech Director Bo Linton , further commented Mr. Dimitrov has an extensive knowledge of the Immunotech "IPF" patented technology and has worked alongside the company for several years, assisting with International awareness and potential Clinical Trial progression for the company's Immunotherapy Treatments.

Immunotech President Harry Zhabilov commented, "We are very pleased to announce the appointment of Valentin to the Board of Directors and feel he will be a valuable member of our team, and significantly help accelerate the progression of the company towards FDA approval for the 'IPF' technology."

The appointment of Mr. Dimitrov to Immunotech's Board of Directors helps with the potential goal of upgrading the company to the NASDAQ exchange, where a minimum of 5 Board Members are required.About Valentin Lordanov DimitrovEDUCATION:Kliment Ohridski University

Master's degree - Social PedagogicsKiev State University, Ukraine

Bachelor of International Diplomatic RelationsSPECIALIZATIONS:1995:

University of National and World Economy – Sofia - Finances1999:

Chemical-technological University - Sofia - Organic chemistry LANGUAGES:English - Fluent , Russian - fluent , German – spokenPROFESSIONAL BACKGROUND:2007-Current: "Vital-Fe" LTD – Distribution of bio-technology and pharmaceutical products – Director2003-Present"Bulgarian Association of Chemical and Fertilizer Industry" – Chairman2002-2003"Chimco Vienna" GmbH – Distributor of chemical and pharmaceutical products – Director1999-2002"CHIMCO" JSC, Vratza - Chemical production plant - Chairman of the Board of Directors1992-1998"Prima Gas" JSC – supply of natural gas – Director1995-1996"International Orthodox Bank" – (present "Investbank" JSC), Founder and member of the Supervisory Board1994-1995"Private Agricultural and Investment Bank" – Member of the Supervisory Board1990-1991 "Pharmachem" JSC – pharmaceutical and chemical industry – Director of DepartmentSafe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Company Contact:
ir@immunotechlab.com

Investor Relations:
The Nabors Group: 713-875-9200
E-mail: naborsgroup@yahoo.com
www.facebook.com/Naborsgroup  

CSNNewswire – Be Seen
www.csnnewswire.com


'/>"/>
SOURCE Immunotech Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Oz, Host Of The Dr. Oz Show, and Harry Zhabilov Of Immunotech Laboratories Discuss Immunotherapy Treatments For Cancer, HIV/AIDS
2. Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures
3. Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines
4. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
5. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
6. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
7. Heraeus Named "Supplier of the Year" by National Association of Dental Laboratories
8. New Jensen Dental White Paper Reveals How Dental Laboratories Can Increase Productivity, Profitability with a Multi-Function Pressing Furnace
9. AAIPharma Announces Promotion Of Dean Shirazi To EVP Of Analytical Laboratories
10. IDEXX Laboratories Announces Entry Into Consent Agreement with FTC Bureau of Competition Staff
11. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... H1 2016" market research report that provides an ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:4/28/2016)... 28, 2016   Click here for supplemental ... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ... agreement to acquire Valley Campus Pharmacy, Inc., doing ... leading specialty pharmacy that provides individualized patient care, ... . In 2015, TNH generated approximately $400 million ...
(Date:4/28/2016)... 28, 2016  The blood testing market in ... to Kalorama Information and The Freedonia Group in a ... acid testing.  The healthcare research firm said that ... blood collection stations and in improving testing at the ... report, Blood Testing Market in China ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... , ... Mobility Designed is redefining mobility with their patent pending crutch ... evenly distributes body weight from the elbow to the forearm. In consumer tests, ... with other crutches. , Co-founders Max and Liliana Younger were inspired to design the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Association (CCA), is pleased to announce the launch of the GFCP Scoop ... recipes, and more. The purpose of the GFCP Scoop site is ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering the many ... learn more about the options currently available to them and which ones might work ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly ... for the head and neck/ear, nose and throat specialty, has added the KOTLER NASAL ... KOTLER NASAL AIRWAY™ is a newly patented safety device secured by nasal surgeons ...
(Date:4/29/2016)... ... 2016 , ... Jvion, the market leader in clinical predictive ... Partners, with participation from existing investor Martin Ventures. The funds will be ... and product roadmap. , “Jvion is experiencing significant growth and we ...
Breaking Medicine News(10 mins):